Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000926 · ClinicalTrials.gov registry record · Phase 3
A Study of Nonoxynol-9 (N-9) and HIV Infection
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 4,400
- Enrollment target
NCT00000926: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000926 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,400 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (470% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000926, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,400 participants
- Enrollment target
Study Summary
The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV. Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases.
Interventions
- DRUG Nonoxynol-9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,400 participants |
| Est. Completion | 2001-02 |
| Phase | Phase 3 |
What the finished NCT00000926 record still lists
NCT00000926 is an interventional study that assigns participants to a tested intervention. Its 4,400 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (470% higher).
The record links to 0 conditions, and to 1 intervention - of which Nonoxynol-9 is the first listed.
NCT00000926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000926 about?
NCT00000926 is a clinical study titled "A Study of Nonoxynol-9 (N-9) and HIV Infection". The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV. Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9...
What is the current status of trial NCT00000926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,400 participants. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00000926?
The interventions under investigation include: Nonoxynol-9 (DRUG).
Who is sponsoring clinical trial NCT00000926?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000926's enrollment target sits among peer trials
4,400 56th of 2000 higher than 1,945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R